Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined

immune checkpoint inhibition

Mick J.M. van Eijs,[1,2,#] Rik J. Verheijden,[1] Stefanie A. van der Wees,[2] Stefan Nierkens,[2,3] Anne S.R. van

Lindert,[4] Karijn P.M. Suijkerbuijk[1,*], Femke van Wijk;[2,*] on behalf of the UNICIT Consortium[†]

[1] Department of medical oncology, University Medical Center Utrecht, Utrecht, the Netherlands
[2] Center for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands
[3] Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
[4] Department of pulmonology, University Medical Center Utrecht, Utrecht, the Netherlands
10
11 * Contributed equally
12 # Corresponding author: Mick J.M. van Eijs. Internal mail no. KC.02.085.2, P.O. Box 85090, 3508 AB, Utrecht, the
13 Netherlands; T: +31 (0)88 757 7183; E: m.j.m.vaneijs-2@umcutrecht.nl
14
15 **† Collaborators UNICIT consortium**: Linde Meyaard, Jürgen H.E. Kuball, Bas Oldenburg, Jeanette H.W. Leusen.

Abstract

Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs). Mechanistic studies can aid the transition from expert-opinion to evidence-based irAE treatment strategies. We aimed to longitudinally characterize peripheral blood T and B cell dynamics in ICI-treated patients by multicolor flow cytometry and serum multiplex immunoassay at baseline, ±3 weeks and ±6 weeks or upon clinically relevant irAEs. We analyzed samples from 44 ICI-treated patients (24 anti-PD-1 monotherapy, 20 combined anti-PD-1/anti-CTLA-4; cICI), of whom 21 developed irAEs, and 10 healthy donors. IrAEs after cICI were characterized by significantly enhanced proliferation of Th1-associated, mainly (CD4$^+$) effector memory T cells, as well as Th17-associated immune responses and germinal center activation (reflected by CXCL13 and IL-21 increases). We observed no changes in CD21^{lo}, memory, class-switched or newly activated B cell subsets. Especially double-positive PD-1$^+$LAG-3$^+$ CD8$^+$ T cells showed enhanced cytotoxic capacity in patients with irAEs after cICI. Within anti-PD-1 monotherapy, irAEs were associated with modestly enhanced Th1-associated responses reflected by increased serum CXCL9 and CXCL10. In conclusion, ICI-induced toxicity is dominated by enhanced Th1-associated responses, but in cICI we also found evidence for Th17-associated responses and germinal center activation. Together, our data add to the growing body of evidence that irAEs may be driven by newly activated CD4$^+$ helper T cells, specifically after cICI. This study also supports tailored irAE treatment, based on ICI regimen, and to deploy specific strategies such as Th17 inhibition especially in cICI-associated irAEs.

Keywords: Immune checkpoint inhibitors, Immune-related adverse event, peripheral blood, immunophenotyping, T and B lymphocytes.

Introduction

Immune checkpoint inhibitors (ICI) have realized unprecedented survival improvements in a selection of patients with advanced malignancies, but comes with a broad spectrum of immune-related adverse events (irAEs) [1]. To date, recommendations for irAE management are largely based on multidisciplinary expert consensus [2-4]. In quest of rationally developed treatment strategies, it has been suggested to draw on experience with specific autoimmune diseases (AD) these irAEs mimic, assuming shared pathophysiology [1]. Despite similarities, immune-related toxicity should clinically be considered a separate disease entity, for instance illustrated by the more acute onset and possibility of complete irAE reversibility with adequate therapy. Together with the concern that targeted immunosuppression may thwart antitumor immunity [5, 6], these observations underscore that evidence-based irAE treatment requires more profound biological understanding of specific mechanisms underlying ICI-induced toxicity.

Many efforts have been undertaken to predict irAEs at baseline or early on-treatment based on peripheral blood immune cells, cytokines, auto-antibodies and gut microbiome, as extensively reviewed in Hommes et al. [7]. Relatively higher blood lymphocyte count at baseline has been associated with development of irAEs [7]. Several studies that further characterized T and B cells at baseline and on-treatment reported a multitude of factors associated with irAE development, such as proliferation of (activated) $CD4^+$ and $CD8^+$ T cell subsets, baseline Th17 dominance and early increase in $CD21^{lo}$ B cells [8-12]. Most of these findings still warrant replication. Particularly effector memory $CD4^+$ T cells ($CD4_{EM}$) have recently been suggested as drivers of irAEs [10, 13, 14]. $CD4^+$ T cell clonal expansion preceding irAEs [10, 15] and indications for epitope sharing between tumor and irAE-affected tissue [16, 17] suggests a role for T cell auto-reactivity in irAE development [10, 13]. However, the concept of genuine autoimmunity does not seem to completely recapitulate the pathophysiology of irAEs.

Longitudinal studies into general irAE mechanisms comparing different ICI regimens are lacking, but urgently needed to improve irAE treatment strategies [18]. Besides, the role of B cells in irAEs has received little attention. Therefore, we interrogated peripheral T and B cell dynamics and cytokine production from baseline to several weeks on-treatment and upon immune-related toxicity in anti-PD-1 monotherapy and combined anti-CTLA-4 and anti-PD-1 (cICI) treated patients.

Methods

Study population and design

We included patients from the UNICIT biobank study conducted within the University Medical Center Utrecht (UMCU), Utrecht, the Netherlands. Adult patients undergoing a first regimen of ICI with anti-PD-1 monotherapy, combined anti-CTLA-4 and anti-PD-1 (cICI), or anti-PD-(L)1 in combination with chemotherapy for a solid malignancy are prospectively enrolled in this biobank. Stool and blood samples are collected at baseline, 3-4 weeks and 6-8 weeks after treatment initiation, and upon onset of irAEs prior to initiation of immunosuppressive therapy. Furthermore, stool and blood samples are collected after every new line immunosuppression administered for irAEs. If patients undergo diagnostic procedures for suspected immune-mediated toxicity, extra biopsies of irAE affected tissue are obtained. Tumor response to ICI per RECIST 1.1 [19], irAE incidence and severity per CTCAE version 5 [20], as well as doses and duration of all immunosuppressives administered for irAEs are continuously recorded.

Samples from patients treated with cICI or anti-PD-1 monotherapy (without chemotherapy) were used in the present study. We included peripheral blood mononuclear cell (PBMC) and serum samples collected at baseline, at 3-4 weeks, and at 6-8 weeks for patients without (NOTx) or at irAE onset for patients with clinically relevant toxicity (TOX). 'Clinically relevant toxicity' was defined as CTCAE v5 grade ≥2 irAEs leading to 1) temporary or permanent ICI discontinuation, and 2) demanding hospitalization and/or ≥0.5 mg/kg daily prednisone as first-line immunosuppression. Healthy donor PBMCs were obtained from the UMCU Mini Donor Service (MDS).

Blood sample processing and flow cytometry

PBMCs were isolated using Ficoll-Paque density-gradient centrifugation (GE Healthcare), frozen in RPMI-1640 medium (Gibco) supplemented with 2 mM L-glutamine (L-glu; Gibco), 100 IU/ml penicillin-streptomycin (p/s; Gibco), 20% fetal bovine serum (FBS; Invitrogen) and 10% DMSO (Sigma-Aldrich) and stored at -180°C. Serum was isolated and frozen at -80°C within 4 hours after blood collection.

Thawed PBMCs were plated at $0.5–1.0×10^6$ cells per well. Prior to staining, cytokine-containing panels were restimulated with 20 ng/ml phorbol 12-myristate 13-actetate (PMA; Sigma-Aldrich) and 1.0 µg/ml ionomycin (Sigma-Aldrich; 4h, 37°C, 5% CO_2). Golgistop (0.26% monensin; BD Biosciences, 1:1,500) was added for the last 3.5h. Cells were first incubated (30min., 4°C) with eBioscience Fixable

Viability Dye eFluor506 (Invitrogen), washed and then incubated with the surface antibody mix

(**Supplementary Table 1**) in FACS buffer (phosphate buffered saline [PBS, Sigma-Aldrich], 2% FBS,

0.1% sodium azide; 25min., 4°C). On-treatment PD-1 expression was measured indirectly using

biotinylated anti-human IgG4 alone (for unstimulated) or combined with anti-PD-1 (for stimulated panels)

[21], followed by secondary staining with BV711-conjugated streptavidin (30min., 4°C). After fixation

and permeabilization with eBioscience fixation/permeabilization reagent (Invitrogen; 30min., 4°C) and

washing, cells were incubated (30min., 4°C) with the intracellular/intranuclear antibody mix

(**Supplementary Table 1**) and then measured the same or next day on an LSR Fortessa. FlowJo

software was used to analyze data; gating strategies are in **Supplementary Fig. 5a-b**.

Multiplex immunoassay

Concentrations of 23 soluble factors (**Supplementary Table 2**) were measured in serum collected at

the same timepoints as PBMCs by an in-house developed and validated immunoassay based on

Luminex technology (xMAP, Luminex) at the Multiplex Core Facility (UMCU) [22, 23]. Aspecific

heterophilic immunoglobulins were preabsorbed with heteroblock (Omega Biologicals) and acquisition

was performed with the Biorad FlexMAP3D (Biorad laboratories) in combination with xPONENT

software (v4.2, Luminex). Data was analyzed by 5-parametric curve fitting using Bio-Plex Manager

software (v6.1.1, Biorad). Serum samples from 10 healthy donors other than PBMC healthy donors were

obtained from the UMCU MDS (median age 35 years, range 26-61; 60% male sex). For one patient no

serum was available. Undetectable values below the limit-of-detection (LOD) were replaced with

0.5×LOD.

Unsupervised and statistical analysis

Analyses were performed with R version 4.2.0. For principal component analysis (PCA), missing data

were imputed with the population median per parameter and PCA was performed using *prcomp()* in

stats (v3.6.2) on all 159 read-out parameters across all panels. t-Distributed stochastic neighbor

embedding (t-SNE) projections for panel 2 (**Supplementary Table 1**) were created using *Rtsne* (θ=0.5;

v0.16) and k-means clustered self-organizing maps (SOMs) using FlowSOM (v2.4.0) [24] with a random

10% subset of pre-gated alive CD3$^+$ singlets drawn from samples upon timepoint 3, toxicity or healthy

donor. Longitudinal continuous data were analyzed by linear mixed effects models using the *nlme*

package (v3.1-158). Random intercept for subject models with fixed effects for ICI regimen, toxicity

status and their interaction with time were fit by restricted maximum likelihood. Significance for fixed

effects was evaluated with Satterthwaite approximations given relatively small sample size [25]. Model

output was visualized as predicted population estimates with 95% confidence intervals (CIs). Mean and

95% CI (by one-sample t-test) for healthy donor values was plotted as solid and dashed grey lines,

respectively. Continuous variables were analyzed with one-sample t tests for single groups, or a

Wilcoxon rank sum test (for unpaired) or Wilcoxon signed-rank test (for paired data) between two

groups. More than two groups were compared with the Kruskal-Wallis test followed by Dunn's post-hoc

test with Benjamini-Hochberg false discovery rate correction. *P* values <0.05 (two-sided) were

considered statistically significant.

Ethics approval

The UNICIT biobank study was not considered subject to the Dutch Medical Research with Human

Subjects Law by the medical research ethics committee of the UMCU. The biobank review committee

of the UMCU approved the UNICIT biobank protocol (TCbio 18-123) and granted permission for use of

human biospecimens for the present study (TCbio 19-704). All participants provided written informed

consent in line with the Declaration of Helsinki.

Results

Patient characteristics

Longitudinal PBMC and serum samples collected at baseline, at ±3 weeks (Timepoint 2) and at ±6

weeks or upon irAEs before immunosuppression (Timepoint 3/Toxicity) from 44 ICI-treated patients (11

anti-PD-1 monotherapy with clinically relevant irAEs [TOX], 13 anti-PD-1 monotherapy without clinically

relevant irAEs [NOTx], 10 combined ICI [cICI] TOX and 10 without TOX [cICI NOTx]) were included,

along with 10 healthy donors (HD) (**Fig. 1**, **Table 1**, **Supplementary Table 3**). As expected for cICI

TOX, these patients had more concomitant, earlier-onset and more severe irAEs than anti-PD-1 TOX

patients (**Table 1**). Baseline absolute eosinophil count, monocyte-to-lymphocyte and neutrophil-to-

lymphocyte ratios derived from complete blood counts were equal between TOX and NOTx patients, as

well as T cell-to-monocyte ratio assessed by flow cytometry.

Table 1. Characteristics of patients and healthy donors

	Anti-PD-1 NOTx (N=13)	Anti-PD-1 TOX (N=11)	cICI NOTx (N=10)	cICI TOX (N=10)	Healthy donor (N=10)	*P* value
Age (yr)						
Median (IQR)	63.0 (57-69)	73 (66.5-76.5)	71.0 (58.25-75)	49.5 (45.5-62.75)	56.0 (38.75-60.75)	**<0.01**
Sex (male), N (%)	9 (69.2)	8 (72.7)	10 (100)	8 (80.0)	3 (30.0)	**0.012**
Primary tumor, N (%)						
Melanoma	9 (69.2)	9 (81.8)	3 (30.0)	8 (80.0)	N/A	**<0.01**
Non-small cell lung cancer	0 (0.0)	1 (9.1)	0 (0.0)	0 (0.0)		
Renal cell carcinoma	1 (7.7)	0 (0.0)	6 (60.0)	2 (20.0)		
Urothelial cell carcinoma	3 (23.1)	0 (0.0)	0 (0.0)	0 (0.0)		
Other	0 (0.0)	1 (9.1)[a]	1 (10.0)[b]	0 (0.0)		
Tumor stage, N (%)						
III	4 (30.8)	4 (36.4)	0 (0.0)	0 (0.0	N/A	**0.031**
IV	9 (69.2)	7 (63.6)	10 (100.0)	100 (100.0)		
Time-to-toxicity (weeks)						
Median (IQR)	N/A	8.0 (6-12)	N/A	4.5 (3-6)	N/A	0.076
Number of toxicities						
1	N/A	9 (81.8)	N/A	5 (50.0)	N/A	0.28
2		2 (18.2)		2 (20.0)		
3		0 (0.0)		2 (20.0)		
>3		0 (0.0)		1 (10.0)		
Highest grade (CTCAE v5)						
II	N/A	8 (72.7)	N/A	0 (0.0)	N/A	**<0.01**
III		2 (18.2)		8 (80.0)		
IV		1 (9.1)		2 (20.0)		
Preexistent autoimmune disease, N (%)	0 (0.0)	0 (0.0)	1 (10.0)	0 (0.0)	0 (0.0)	0.45

[a]Squamous cell carcinoma of unknown primary, [b]Mismatch repair deficient colorectal cancer. Groups are compared by Kruskal-Wallis (continuous variables) or Fisher's exact test (categorical variables). Abbreviations: anti-PD-1 denotes 'anti-PD-1 monotherapy', cICI 'combined immune checkpoint inhibition', CTCAE 'Common Terminology Criteria for Adverse Events', IQR 'interquartile range', N/A 'not applicable', NOTx 'no clinically relevant irAEs', TOX 'with clinically relevant irAEs', yr 'years'.

CD4$_{EM}$ T cell proliferation is strongly associated with irAEs in combined ICI

We extensively characterized the dynamics of peripheral T and B cell immunity during ICI treatment and towards the manifestation of toxicity using multicolor flow cytometry. We explored shared features among subjects, with principal component analysis (PCA) with all 159 readout parameters from panels in **Supplementary Table 1** pooled together. cICI TOX patients, especially on-treatment timepoints, partially separated from all other subjects, including healthy donors, mainly through principal component 2 (**Fig. 2a**, **Supplementary Table 4**).

Based on the expression of CD27 and CD45RA, distributions of CD4$^+$ and CD8$^+$ T effector memory (EM, CD27$^-$CD45RA$^-$), central memory (CM, CD27$^+$CD45RA$^-$), terminally differentiated effector memory re-expressing CD45RA (EMRA, CD27$^-$CD45RA$^+$) and naive (CD27$^+$CD45RA$^+$) subsets were analyzed. Although pre-treatment CD4$_{EM}$ frequency has been reported as irAE predictor [10], baseline proportions of CD4$^+$ and CD8$^+$ T subsets were similar between TOX and NOTx patients (**Supplementary Fig. 1a**). Compared to ICI-treated patients, healthy donors had fewer CD4$_{EM}$ T cells and more naive CD8$^+$ T cells (**Supplementary Fig. 1a**). During ICI treatment, and even upon onset of irAEs, relative frequencies of naive/memory subsets remained unchanged, except for an increase in

CD8$_{EM}$ T cells in cICI TOX (**Supplementary Fig. 1b**). However, group-specific differences in proliferation

(based on Ki67) over time were present. A significant increase in CD4$_{EM}$ proliferation from baseline to

Timepoint 2 was observed in all cICI TOX patients, but not in cICI NOTx patients (**Fig. 2b**). To enable

comparison of all five groups (TOX or NOTx in anti-PD-1 monotherapy or cICI and healthy donors)

simultaneously and over time, we graphically summarized patient-level data by plotting group-specific

linear mixed models. cICI TOX, but not NOTx or anti-PD-1-treated patients showed significantly

increased proliferation in CD4$_{EM}$, CD4$_{CM}$, CD8$_{EM}$, CD8$_{CM}$ and CD8$_{EMRA}$ T cells (**Fig. 2c,d**,

Supplementary Fig. 1c-e).

211   While the latter effects pertain to the (early) effects of ICI treatment, we were also interested in

baseline parameters associated with irAE development. Higher CD4$_{EM}$ proliferation before the first ICI

administration was associated with shorter time-to-toxicity (ρ = -0.53, *P* = 0.013), but this association

was entirely driven by the cICI group (ρ = -0.67, *P* = 0.034, **Fig. 2e**). In most cICI treated TOX patients,

the increase in Ki67 expression reached a plateau at 3 weeks after ICI initiation (**Fig. 2b**). Both cICI

TOX patients with longest time-to-toxicity developed hypophysitis, a presumably complement-mediated

irAE with distinct pathogenesis from most other toxicities [26]. This further strengthens the association

of baseline CD4$_{EM}$ proliferation with early-onset toxicity after cICI.

Th1- and Th17-associated immune responses primarily delineate irAEs after combined ICI, while

anti-PD-1 TOX features only a modest Th1-associated response

Expanding further on the CD4$^+$ compartment, we investigated immune response skewing by the

percentages of CXCR3$^+$CCR4$^-$, IFN-γ^+ and IL-17$^+$ CD4$^+$ T cells. Relative abundance of all three subsets

remained constant over time and neither correlated with ICI regimen, nor with toxicity development (data

not shown). Although we found no differences in the percentage of IFN-γ^+ CD4$^+$ T cells over time (**Fig.**

3a), cycling CXCR3$^+$CCR4$^-$ (Th1-associated) CD45RO$^+$ memory CD4$^+$ T cells were dominant in cICI

TOX relative to all other groups (**Fig. 3b**). Correspondingly, we observed increased proliferation of

CXCR3$^+$ CD45RO$^+$ memory CD8$^+$ T cells in cICI TOX patients (**Supplementary Fig. 2a**). These findings

were corroborated by serum multiplex data, which showed increased serum levels of Th1-associated

cytokines IL-12, TNF-α and IFN-γ in cICI TOX, and CXCL9 and CXCL10 both in anti-PD-1 and cICI TOX

upon Timepoint 3/Toxicity (**Fig. 3c,d**, **Supplementary Fig. 2b–e**).

We further characterized the kinetics of IL-17 producing CD4[+] T cells, which is especially

relevant since inhibition of Th17 differentiation by the IL-6 receptor blocker (IL-6RB) tocilizumab is

clinically being tested to uncouple ICI toxicity from efficacy [27]. After the first treatment cycle, cICI TOX,

but not anti-PD-1 TOX or NOTx patients demonstrated a vast increase in IL-17[+] T cells (**Fig. 3e**,

Supplementary Fig. 2f). Ki67 expression in IL-17[+] CD4[+] T cells was non-significantly higher in TOX

compared to NOTx across all timepoints, including baseline, regardless ICI regimen (**Supplementary**

Fig. 2g). The relative decrease of IL-17[+] T cells from timepoint 2 to irAE onset in cICI TOX is likely due

to relative expansion of other subsets, as serum concentrations of Th17-associated cytokines IL-6, IL-

23 and IL-17 remained stable or even increased from Timepoint 2 towards irAE onset (**Fig. 3c**,

Supplementary Fig. 2c) while IL-23 and IL-17 even show a greater than eightfold increase in cICI TOX

compared to cICI NOTx patients at Timepoint 3/Toxicity (**Supplementary Fig. 2e**).

Together, our data confirm that cICI TOX is largely Th1/Th17 driven, while anti-PD-1 TOX only

features modest Th1 enhancement relative to anti-PD-1 NOTx as assessed by serum multiplex data.

Furthermore, these human data suggest that IL-6RB therapy to mitigate ICI toxicity may be more

effective in cICI than in anti-PD-1 monotherapy, although preclinical models have demonstrated its

efficacy both in anti-CTLA-4 and anti-PD-1 monotherapies [27].

PD-1[+]LAG-3[+] CD8[+] T cells bear intact inflammatory and cytotoxic potential regardless

development of irAEs

Next, we investigated the cytotoxic potential of CD4[+] and CD8[+] T cells in relation to co-inhibitory receptor

expression. We used CD95 expression to select for the antigen-experienced CD8[+] T cell pool [28], which

largely overlaps with CD45RO[+] memory cells but also includes T$_{EMRA}$s (**Fig. 4a**). First, we created t-SNE

and FlowSOM visualizations of CD3[+] T cells from Timepoint 3/Toxicity across all patients and healthy

donors, to explore the variety of subsets in an unbiased way. Proinflammatory cells with high potential

for IFN-γ production were represented mainly across the CD8[+] compartment (**Fig. 4b**). Within the CD8[+]

compartment, granzyme B production was especially high in the subset expressing senescence marker

CD57 (**Fig. 4b**). Although this subset appeared brighter in the anti-PD-1 and cICI TOX density plots

(**Fig. 4b**), we found no statistical difference in CD57[+] CD8[+] T cell abundance between groups at

Timepoint 3/Toxicity. Labels assigned based on manual gating matched unsupervised clustering results,

demonstrating that our gating strategy adequately covers relevant biological variation (**Supplementary**

Fig. 3a).

Subsequentially, we investigated co-expression patterns of classical exhaustion markers PD-1 and

LAG-3. At baseline, PD-1$^+$LAG-3$^+$ double-positive (DP) CD8$^+$ T cells were least prevalent across groups,

while DP CD4$^+$ T cells were higher and made up the largest fraction of CD4$^+$ T cells in both TOX and

NOTx patients, compared to healthy donors (**Fig. 4c**). We found no differences in expression patterns

of PD-1 and LAG-3 occurring between TOX and NOTx post-treatment (**Supplementary Fig. 3b**).

Since merely expression of inhibitory receptors is not indicative of differentiation or functional status,

we assessed proinflammatory and cytotoxic capacity by measurement of IFN-γ and granzyme B

production after restimulation with PMA and ionomycin. Compared to double-negative (DN) T cells, a

much larger proportion of DP (and to a lesser extent PD-1$^+$LAG-3$^-$) CD8$^+$ T cells produced IFN-γ (**Fig.**

4d,**e**). This indicates preserved proinflammatory potential of DP cells and is supported by transcriptomic

data in circulating PD-1$^+$TIGIT$^+$ CD8$^+$ T cells, mostly co-expressing LAG-3, in melanoma and Merkel cell

carcinoma [29]. In contrast, we found that granzyme B production was drastically lower in DP relative to

DN CD8$^+$ T cells, regardless timepoint or the development of irAEs (**Supplementary Fig. 3c,d**). Still,

cICI TOX featured a profound increase in CD8$^+$ granzyme B production over time relative to other

groups, especially in the DP subset (**Fig. 4f**, **Supplementary Fig. 3e,f**).

In conclusion, our data suggest remaining cytokine production potential in supposedly senescent

CD57$^+$ CD8$^+$ T cells. Moreover, PD-1$^+$LAG-3$^+$ DP CD8$^+$ T cells retain their proinflammatory and cytotoxic

potential, while towards irAEs after cICI the fraction of granzyme B producing cells increases especially

in this DP subset.

No changes in B cell subsets are observed, but serum cytokine levels indicate germinal center

activation in combined ICI TOX

Then we set out to analyze the CD19$^+$ B cell compartment over time. Although early increase in CD21^{lo}

B cells (mainly representing a memory subset) has been associated with irAEs following cICI [11, 30],

we found no changes in CD21^{lo} B cells following ICI, while CD27$^+$ memory B cells in cICI TOX even

decreased (**Fig. 5a,b**). Moreover, we observed no B cell activation, measured by CCR6 expression

(**Supplementary Fig. 4a**). The fraction of IgM$^-$ class-switched B cells also remained unchanged over

time in all groups (**Supplementary Fig. 4b**). Despite lacking indications for B cell activation and

maturation based on flow cytometry data, increasing serum levels of APRIL, CXCL13 and IL-21 towards

toxicity suggest germinal center activity or tertiary lymphoid structure (TLS) formation, again especially

in cICI TOX (**Fig. 5c**, **Fig. 3c**, **Supplementary Fig. 2b,c**). Besides, higher CD27$^+$CD38^{hi} plasmablast

abundance at baseline was associated with shorter time-to-toxicity in cICI TOX (**Fig. 5d**). In sum, these

data support a role for adaptive humoral immunity following cICI that is more pronounced in TOX than

NOTx, although no changes of B cell abundances were observed in peripheral blood.

Regulatory activity by Tregs is preserved upon systemic inflammation in the context of irAEs

Finally, we sought to characterize the response of regulatory T (Treg) cells after ICI treatment.

Abundance of forkhead box protein 3 (FOXP3)$^+$ CD25$^+$ CD4$^+$ Tregs increased over time, especially in

cICI TOX patients (**Fig. 6a**). Already at baseline, Tregs from patients showed higher expression of T-

box transcription factor TBX21 (T-bet) compared with healthy donors (**Fig. 6b**). This may be indicative

of a more activated Th1-polarized state, even before the introduction of ICI. To assess whether Tregs

can adequately respond to systemic inflammation inflicted by ICI, we compared expression levels of co-

inhibitory and co-stimulatory receptors. At Timepoint 3/Toxicity, mainly cICI TOX patients clustered

together, marked by upregulation of CTLA-4, ICOS and TIGIT (**Fig. 6c**). Notably, the only two cICI TOX

patients with grade 4 irAEs clustered distinctly, characterized by Tregs that failed to upregulate CTLA-

4 or TIGIT. In sum, these findings indicate that peripheral Treg function upon systemic inflammation is

generally preserved after ICI, while Treg dysfunction may contribute to more severe irAEs.

Discussion

Longitudinal studies into mechanisms underlying irAEs can importantly contribute to establishing

evidence-based treatment strategies. Therefore, we studied lymphocyte dynamics in peripheral blood

of healthy donors and ICI-treated patients with and without irAEs from baseline to several weeks into

treatment. Key findings are that cycling Th1-associated effector memory CD4$^+$ T cells appear important

drivers of acute irAEs, specifically in cICI. Besides, Th17- and Th2-associated responses contribute to

the development of irAEs following cICI, but no changes in abundance or activation of B cell subsets

were found. In contrast, anti-PD-1-associated irAEs were characterized by a modestly enhanced Th1

response compared to anti-PD-1-treated patients without irAEs. This likely relates to the less acute

nature of anti-PD-1 associated toxicity. We showed that peripheral blood PD-1$^+$LAG-3$^+$ CD8$^+$ T cells

retained their proinflammatory potential and that especially within this DP subset the fraction of

granzyme B producing cells increases towards cICI TOX relative to other patient groups.

Our key findings are corroborated by a recent study which showed that irAEs are associated

with early proliferation of peripheral blood (activated) CD4$^+$ and CD8$^+$ T cell subsets in a Th1-skewed

milieu (based on serum CXCL9/10/11 and IFN-γ) [9]. In contrast to our findings, this group also found a

cellular Th1-associated response for irAEs after anti-PD-1. This may be due to the difference in sampling

of the first on-treatment timepoint at 7-14 days in [9] versus ±3 weeks in our study. Indeed, Nuñez et al.

found that at later timepoints the percentage activated CD4$^+$ and CD8$^+$ of all T cells had returned to

baseline levels in patients with irAEs [9]. This also fits the observation that cycling CD8$^+$ T cells peak at

seven days after anti-PD-1 treatment before they gradually return towards baseline levels three weeks

post-treatment [31], possibly because of migration of proliferating cells into tissues.

ICI may induce proliferation and reinvigorate antitumor responses in different non-terminally

exhausted cell populations, including PD-1$^+$ CD8$^+$ T cells [32, 33]. We showed that PD-1$^+$LAG-3$^+$ (DP) T

cells produced highest amounts of IFN-γ after restimulation, which may indicate intact proinflammatory

potential *in vivo.* However, phenotypically similar T cells may exert differential function dependent on

location [34]. Besides, despite T cell transcriptomic overlap of proinflammatory genes and exhaustion

markers [35, 36], *ifng* translation may be hampered in dysfunctional T cells [37]. In addition to IFN-γ

production, cICI TOX featured a profound increase in granzyme B production over time, especially in

DP CD8$^+$ T cells, which could indicate reinvigoration of dysfunctional cells and *de novo* activation. In

sum, our study presents DP T cells as most potent proinflammatory and cytotoxic cells, but to what

extent this potential is deployed *in vivo* likely depends on ICI regimen.

We observed ongoing proliferation in the CD8$^+$ and, most prominently, CD4$^+$ memory pools in

cICI TOX. Our results are consistent with other studies indicating increased CD4$^+$ and CD8$^+$ clonal

expansion and repertoire diversification in patients with irAEs [10, 15, 38-40]. Moreover, CD4$_{EM}$ T cell

expansion in patients with irAEs parallels CD4 memory abundance in classical autoimmune disease

[10]. Together, these data reinforce the hypothesis that cross- or autoreactive CD4$_{EM}$ clones may be

unleashed upon ICI treatment in some, especially early, irAEs.

Helper T cells may also provide help to autoantibody-producing B cells. In line with an antibody-

mediated etiology, our serum cytokine data (including CXCL13 and IL-21) suggest germinal center

activation or TLS formation both in cICI and anti-PD-1 monotherapy irAEs. CD4$_{EM}$ T cells have been

shown to contribute to thyroiditis development in anti-PD-1 treated mice with preexisting autoimmunity

following anti-thyroglobulin immunization [13]. Recent work by Johannet et al. showed that baseline

serum autoantibody signatures are predictive of severe irAEs (not limited to thyroiditis) with adjuvant

anti-PD-1 and/or anti-CTLA-4 [41], which presents further evidence that preexistent subclinical

autoimmunity may be at the root of various irAEs. Importantly, CXCL13 increase does not *per se* indicate

TLS formation, as tumor-reactive T cells identified through *CXCL13* expression can also be a source

that expands upon treatment in ICI-responders [42].

The role of B cells in irAE development is further solidified by human data on increasing CD21^{lo}

B cells in association with irAEs in the setting of cICI [11, 30]. We were not able to reproduce these

findings, which may be due to different timing in blood collection and B cells migrating into peripheral

tissues shortly following activation. A recent study found that aged anti-PD-1-treated mice developed

TLS-like aggregates in irAE-affected tissue in a CXCL13-dependent fashion and that B cell depletion

could attenuate ICI-inflicted toxicity [43]. So far, the use of rituximab for irAE management is limited to

case reports [44]. These data together with our work reinforce B cells as a potential target for irAE

treatment, although caution is warranted as TLS activation has also been strongly associated with

clinical response to ICI [45].

Strengths of our study include the longitudinal design with multiple on-treatment timepoints, the

stratified analysis for anti-PD-1 and combined ICI treatment and the variety of measured T and B cell

parameters. This allowed investigation of very early treatment-specific immunological effects that

precede irAE onset. Our study has several limitations. First, age and sex were unevenly distributed

among groups. Second, there was considerable heterogeneity in type of irAEs, also within different

strata. However, this simultaneously presents as a strength: we clearly found significant and clinically

relevant differences between groups that would be less generalizable to the general irAE patient

population if obtained within a controlled and irAE-homogenized cohort. Third, our study was powered

to discover irAE-related differences stratified by ICI regimen. Therefore, it did not allow for further

stratification by ICI response, which would moreover require restriction to a single tumor type. Lastly,

our research was limited to the peripheral blood compartment.

In conclusion, we show that the peripheral blood immune response substantially differs between

patients treated with cICI and anti-PD-1 monotherapy, and between cICI-treated patients with and

without irAEs. Toxicity is clearly dominated by enhanced Th1-associated immunity, but we showed that

the Th17 pathway and germinal center activation also contribute to cICI toxicity. In this way, our study

provides rationale to guide irAE treatment schemes based on ICI regimen and to deploy specific T-cell-

directed (second-line) strategies, such as anti-IL-6R, especially in cICI-associated irAEs.

Figure legends

Figure 1 Design of multicolor longitudinal flow cytometry study. Peripheral blood mononuclear cell

(PBMC) and serum samples from immune checkpoint inhibitor (ICI)-treated patients developing or

remaining free of clinically relevant immune-related adverse events (irAEs) were included at baseline,

±3 weeks into treatment and at ±6 weeks or upon irAE onset (for which median time-to-onset and inter-

quartile range are shown). Healthy donor PBMCs and serum were included for comparison. Created

with BioRender.com.

Figure 2 Effector memory CD4$^+$ T cell proliferation increases over time in combined-ICI treated

patients with toxicity, relative to other groups, and is at baseline associated with early irAE

onset. (**a**) Plot showing clustering of different groups in principal component analysis (PCA) with pooled

flow cytometric data including all 159 readout parameters across panels. (**b**) Individual patient

trajectories of the percentage Ki67$^+$ of CD4$^+$ effector memory (CD4$_{EM}$) T cells. Comparison by unpaired

Wilcoxon test because of missing paired data for some patients. (**c**,**d**) Percentage proliferating of total

CD4$_{EM}$ (**c**) and CD8$_{EM}$ (**d**) T cells over time. Only significant coefficients from mixed-effects models for

the interaction term with time ('B'), indicating statistically significant change compared to other groups,

are shown. Gray solid and dashed lines indicate mean healthy donor level with 95% confidence interval.

(**e**) Correlation between baseline CD$_{EM}$ proliferation rate and time-to-toxicity, stratified by ICI-regimen

(by Spearman correlation). irAE: immune-related adverse event, NS: not significant, w/o: without, *

P<0.05

Figure 3 Both Th1- and Th17-associated immune responses are observed in combined-ICI

treated patients with toxicity, whereas only enhanced Th1-associated immunity is associated

with anti-PD-1 associated toxicity. (**a**,**b**) Percentage IFN-γ$^+$ of total CD4$^+$ T cells (**a**) and percentage

proliferating of CXCR3$^+$CCR4$^-$ Th1-associated CD4$^+$ T cells (**b**) over time. Only significant coefficients

from mixed-effects models for the interaction term with time ('B'), indicating statistically significant

change compared to other groups, are shown. Gray solid and dashed lines indicate mean healthy donor

level with 95% confidence interval. (**c**) Heatmap showing serum levels of cytokines and chemokines

after ±6 weeks (T3), upon irAE onset (Toxicity) or in healthy donors. Data are scaled by individual

proteins across timepoints (see **Supplementary Fig. 3b**,**c**), enabling direct comparison of individual

proteins between three timepoints. Unsupervised clustering of patients by Manhattan distance. (**d**)

Volcano plot showing relative increase in serum protein levels at Timepoint 3/Toxicity in all patients with

irAEs (TOX; anti-PD-1 and cICI combined) versus all patients without irAEs (NOTx). Full protein names

are in **Supplementary Table 2**. (**e**) Fold-change in percentage IL-17$^+$ of CD4$^+$ T cells relative to baseline

in cICI-treated patients without irAEs (left; NOTx) and with (right; TOX) irAEs. irAE: immune-related

adverse event, NS: not significant, w/o: without.

Figure 4 PD-1$^+$LAG-3$^+$ double positive CD8$^+$ memory T cells retain their inflammatory potential

regardless the development of toxicity. (**a**) Representative flow cytometry plot of CD95 and CD45RO

expression in CD8$^+$ T cells. (**b**) t-SNE visualizations for a random 10% subset of all CD3$^+$ T cells from

all patients at Timepoint 3/Toxicity and healthy donors, with relative abundance shown in density plots

(top) and expression of lineage markers, IFN-γ and granzyme B in overlay plots (bottom). (**c**) Baseline

percentages of CD45RO$^+$ CD4$^+$ (left) and CD95$^+$ CD8$^+$ (right) T cells positive for PD-1 alone or PD-1

and LAG-3. Comparisons by Kruskal-Wallis tests. (**d**,**e**) Percentages of CD95$^+$CD8$^+$ T cells producing

IFN-γ after PMA/ionomycin stimulation, depending on inhibitory receptor expression pattern, in patients

without (**d**) or with irAEs (**e**) stratified by time of sample collection; anti-PD-1- and cICI-treated patients

are combined. Comparisons by pairwise paired Wilcoxon tests with Benjamini-Hochberg correction for

multiple testing. (**f**) Percentage of granzyme B producing PD-1$^+$LAG-3$^+$ CD95$^+$CD8$^+$ T cells over time.

Significant coefficient (interaction term with time; 'B') from mixed-effects model is shown. Gray solid and

dashed lines indicate mean healthy donor level with 95% confidence interval. cICI: combined ICI, irAE:

immune-related adverse event, NS: not significant, w/o: without. * $P<0.05$, ** $P<0.01$, *** $P<0.001$, ****

$P<0.0001$.

Figure 5 Increasing serum CXCL13 levels and higher baseline plasmablast abundance in

patients with early toxicity suggest a role for adaptive humoral immunity in toxicity after

combined ICI. (**a-c**) Percentages of CD21^{lo} (**a**) and CD27$^+$ memory (**b**) B cells of total B cells and serum

level (in pg/ml) of CXCL13 (**c**) over time. Only significant coefficients (interaction terms with time; 'B') from mixed-effects models are shown. Gray solid and dashed lines indicate mean healthy donor level with 95% confidence interval. (**d**) Correlation between baseline percentage CD27[+]CD38[hi] plasmablasts of total B cells and time-to-toxicity, stratified by ICI-regimen (by Spearman correlation). irAE: immune-related adverse event, w/o: without.

Figure 6 Peripheral regulatory T cell abundance and function are generally preserved upon toxicity. (**a**) Percentage of CD25[+]FOXP3[+] CD4[+] Treg cells of total CD4[+] T cells over time. Significant coefficient (interaction term with time; 'B') from mixed-effects model is shown. Gray solid and dashed lines indicate mean healthy donor level with 95% confidence interval. (**b**) Comparison of median fluorescence intensity (MFI) of T-bet in Tregs at baseline between healthy donors and all ICI-treated patients, by Wilcoxon test. (**c**) Expression levels (by MFI) of inhibitory and costimulatory receptors in Tregs (for patients Timepoint 3/Toxicity), hierarchically clustered by Euclidean distance. irAE: immune-related adverse event, w/o: without.

References

1. Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2022;21(7):495-508. doi:10.1038/s41573-021-00259-5

2. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv264-iv266. doi:10.1093/annonc/mdy162.

3. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440

4. Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9(6):e002435. doi:10.1136/jitc-2021-002435

5. Verheijden RJ, May AM, Blank CU, et al. Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res 2020;26(9):2268-2274. doi:10.1158/1078-0432.CCR-19-3322

6. van Not OJ, Verheijden RJ, van den Eertwegh AJM, et al. Association of Immune-Related Adverse

Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncol

2022;8(12):1794-1801. doi:10.1001/jamaoncol.2022.5041

7. Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor

Induced Immune-Related Adverse Events—A Comprehensive Review. Front Oncol

2021;10:585311. doi:10.3389/fonc.2020.585311

8. Nuñez NG, Berner F, Friebel E, et al. Immune signatures predict development of autoimmune toxicity

in patients with cancer treated with immune checkpoint inhibitors. *Med (N Y)*. 2023;4(2):113-129.e7.

doi:10.1016/j.medj.2022.12.007

9. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis

in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017;28(6):1368-1379.

doi:10.1093/annonc/mdx108

10.Lozano AX, Chaudhuri AA, Nene A, et al. T cell characteristics associated with toxicity to immune

checkpoint blockade in patients with melanoma. Nat Med 2022;28(2):353-362. doi:10.1038/s41591-

021-01623-z

11.Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination

immune checkpoint blockade. J Clin Invest 2018;128(2):715-720. doi:10.1172/JCI96798

12.Kim KH, Hur JY, Cho J, et al. Immune-related adverse events are clustered into distinct subtypes by

T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020;9(1):e1722023.

doi:10.1080/2162402X.2020.1722023

13.Yasuda Y, Iwama S, Sugiyama D, et al. CD4[+] T cells are essential for the development of destructive

thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med

2021;13(593): eabb7495. doi:10.1126/scitranslmed.abb7495

14.Hutchinson JA, Kronenberg K, Riquelme P, et al. Virus-specific memory T cell responses unmasked

by immune checkpoint blockade cause hepatitis. Nat Commun 2021;12(1):1439.

doi:10.1038/s41467-021-21572-y

15.Oh DY, Cham J, Zhang L, et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients

Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res 2017;77(6):1322-1330.

doi:10.1158/0008-5472.CAN-16-2324

16. Berner F, Bomze D, Diem S, et al. Association of Checkpoint Inhibitor-Induced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019;5(7):1043-1047. doi:10.1001/jamaoncol.2019.0402

17. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016;375(18):1749-1755. doi:10.1056/NEJMoa1609214

18. Bayless NL, Bluestone JA, Bucktrout S, et al. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. J Immunother Cancer 2021;9(9):e002627. doi:10.1136/jitc-2021-002627

19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026

20. NCI (National Cancer Institute). Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [online]. 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.

21. Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A 2017;114(19):4993-4998. doi:10.1073/pnas.1705327114

22. de Jager W, Prakken BJ, Bijlsma JWJ, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005;300(1-2):124-135. doi:10.1016/j.jim.2005.03.009

23. Scholman RC, Giovannone B, Hiddingh S, et al. Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects. Cytokine 2018;106:114-124. doi:10.1016/j.cyto.2017.10.021

24. van Gassen S, Callebaut B, van Helden MJ, et al. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 2015;87(7):636-645. doi:10.1002/cyto.a.22625

25. Luke SG. Evaluating significance in linear mixed-effects models in R. Behav Res Methods 2017;49(4):1494-1502. doi:10.3758/s13428-016-0809-y

26. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16(9):563-580. doi:10.1038/s41571-019-0218-0

27. Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. Interleukin-6 blockade abrogates
immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022;40(5):509-523.e6.
doi:10.1016/j.ccell.2022.04.004

28. Galletti G, de Simone G, Mazza EMC, et al. Two subsets of stem-like CD8+ memory T cell
progenitors with distinct fate commitments in humans. Nat Immunol 2020;21(12):1552-1562.
doi:10.1038/s41590-020-0791-5

29. Simon S, Voillet V, Vignard V, et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell
subset predictive of response to anti-PD-1 therapy. J Immunother Cancer 2020;8(2):e001631.
doi:10.1136/jitc-2020-001631

30. Nishimura K, Konishi T, Ochi T, et al. CD21lo B Cells Could Be a Potential Predictor of Immune-
Related Adverse Events in Renal Cell Carcinoma. J Pers Med 2022;12(6):888.
doi:10.3390/jpm12060888

31. Kim KH, Cho J, Ku BM, et al. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+
T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clin Cancer Res
2019;25(7):2144-2154. doi:10.1158/1078-0432.CCR-18-1449

32. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with
anti-PD-1 response. Nature 2017;545(7652):60-65. doi:10.1038/nature22079

33. Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical
outcomes in resectable melanoma. Nat Med 2019;25(3):454-461. doi:10.1038/s41591-019-0357-y

34. Wu X, Zhang H, Xing Q, et al. PD-1+ CD8+ T cells are exhausted in tumours and functional in
draining lymph nodes of colorectal cancer patients. Br J Cancer 2014;111(7):1391-1399.
doi:10.1038/bjc.2014.416

35. Zheng L, Qin S, Si W, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science
2021;374(6574). doi:10.1126/science.abe6474

36. Szabo PA, Levitin HM, Miron M, et al. Single-cell transcriptomics of human T cells reveals tissue and
activation signatures in health and disease. Nat Commun 2019;10(1):4706. doi:10.1038/s41467-
019-12464-3

37. Salerno F, Guislain A, Freen-Van Heeren JJ, Nicolet BP, Young HA, Wolkers MC. Critical role of
post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells. Oncoimmunology
2019;8(2):e1532762. doi:10.1080/2162402X.2018.1532762

38. Arakawa A, Vollmer S, Tietze J, et al. Clonality of CD4+ Blood T Cells Predicts Longer Survival With

CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. Front Immunol 2019;10:1336.

doi:10.3389/fimmu.2019.01336

39. Robert L, Tsoi J, Wang X, et al. CTLA4 Blockade Broadens the Peripheral T-Cell Receptor

Repertoire. Clin Cancer Res 2014;20(9):2424-2432. doi:10.1158/1078-0432.CCR-13-2648

40. Subudhi SK, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation

precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A

2016;113(42):11919-11924. doi:10.1073/pnas.1611421113

41. Johannet P, Liu W, Fenyo D, et al. Baseline Serum Autoantibody Signatures Predict Recurrence and

Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade. Clin Cancer Res

2022;28(18):4121-4130. doi:10.1158/1078-0432.CCR-22-0404

42. Liu B, Zhang Y, Wang D, Hu X, Zhang Z. Single-cell meta-analyses reveal responses of tumor-

reactive CXCL13+ T cells to immune-checkpoint blockade. Nat Cancer 2022;3(9):1123-1136.

doi:10.1038/s43018-022-00433-7

43. Tsukamoto H, Komohara Y, Tomita Y, et al. Aging-associated and CD4 T-cell–dependent ectopic

CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events. Proc Natl Acad Sci U

S A. 2022;119(29). doi:10.1073/pnas.2205378119

44. Deftereos SN, Georgonikou D. Effectiveness of rituximab in treating immune-checkpoint-inhibitor-

induced immune-related adverse events: results of a systematic review. Ann Oncol 2021;32(2):282-

283. doi:10.1016/j.annonc.2020.12.001

45. Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautès-Fridman C. B cells and tertiary

lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev

Clin Oncol 2022;19(7):441-457. doi:10.1038/s41571-022-00619-z

Statements & Declarations

Funding: This investigator-initiated study received funding from Bristol Myers Squibb (grant number CA209-6JY), paid to institution.

Competing interests: KPMS has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre, AbbVie, received honoraria from Novartis, MSD and Roche and received research funding

from BMS, Philips and TigaTx. FW has advisory relationships with Janssen and Takeda, and received

research funding from Takeda, Galapagos, BMS, Sanofi, and Leo Pharma.

Author contributions: Conceptualization: FW, KPMS, MJME. Project administration and Resources:

RJV, MJME, ASRL, KPMS. Data curation: MJME, SAW, RJV. Formal Analysis: MJME, FW, KPMS.

Writing - original draft: MJME. Writing – review and editing: all authors. Supervision: FW, KPMS.

Data availability: Data and scripts for statistical analysis are available upon reasonable request.

Ethics approval: This study was approved by the University Medical Center Utrecht biobank committee

(TCbio 18-123).

Consent to participate: All participants provided written informed consent in line with the Declaration

of Helsinki.

Acknowledgements: We thank the patients, their families and caregivers, healthy donors, clinical staff

and UNICIT consortium members. We would like to thank the Multiplex Core Facility of the University

Medical Center Utrecht for performing the multiplex immunoassays.

Collaborators UNICIT consortium: Linde Meyaard, Jürgen H.E. Kuball, Bas Oldenburg, Jeanette H.W.

Leusen.

Figure 1

Combined ICI

Healthy donors
(1 timepoint)

Anti-PD-1 monotherapy

Median 4.5 (3-6) weeks

Median 8 (6-12) weeks

T1 (baseline)

T2 (± 3 weeks)

T3 (± 6 weeks)/Toxicity

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6